27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC's (NASDAQ:HZNP) thyroid eye disorder drug and Epizyme Inc's (NASDAQ:EPZM) tazemetostat for epithelioid sarcoma.
The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.
Conferences
12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California
PDUFA Dates
Aimmune Therapeutics Inc (NASDAQ:AIMT) has a target action date of end of January for its peanut allergy treatment candidate Palforzia. An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its safety.
See Also: 7 Blockbuster Drugs Expected To Be Launched In 2020
Clinical Readouts
Miragen Therapeutics Inc (NASDAQ:MGEN) will make a poster presentation of data from the Phase 1 trial of cobomarsen, a miR inhibitor in patients with aggressive HTLV-1 Associated adult T-cell leukemia/lymphoma. The presentation is scheduled for Friday evening.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Earnings
Tuesday
- Pfizer Inc. (NYSE:PFE) (before the market open)
Wednesday
- Illumina, Inc. (NASDAQ:ILMN) (after the market close)
- Varian Medical Systems, Inc. (NYSE:VAR) (after the market close)
- Hologic, Inc. (NASDAQ:HOLX)
Thursday
- Quest Diagnostics Inc (NYSE:DGX) (before the market open)
- Eli Lilly And Co (NYSE:LLY) (before the market open)
- Biogen Inc (NASDAQ:BIIB) (before the market open)
- Amgen, Inc. (NASDAQ:AMGN) (after the market close)
- Edwards Lifesciences Corp (NYSE:EW) (after the market close)
IPOs
Anpac Bio-Medical Science, which focuses on early cancer screening and detection, has filed to offer 17.50 million shares in an IPO, which is expected to be priced between $14 and $16. The company is seeking to list its shares on the Nasdaq under the ticker symbol "ANPC."
Arcutis Biotherapeutics, a biotech company developing topical therapies for common skin diseases, proposes to offer 7.8 million shares at a price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol "ARQT."
Black Diamond Therapeutics, a precision oncology company, is planning an 8.9-million share IPO to be priced between $16 and $18. The company expects to list the shares on the Nasdaq under the ticker symbol "BDTX."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.